SCHEMBL599593

SCHEMBL599593

CCOC(=O)c1[nH]nc(N)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
HPGD P15428 4/20 0.54
HTT P42858 2/20 0.54
KDM4E B2RXH2 2/20 0.54
RECQL P46063 1/20 0.54
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
ALOX15 P16050 1/20 0.48
PDE4D Q08499 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPK10 P53779 1/20 0.46
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.42
POLB P06746 1/20 0.41
LMNA P02545 2/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9038005 0.81 KDM4C (0.50) ALDH1A1HPGDHTTALOX15HSD17B10
SCHEMBL27140315 0.81 PDE4D (0.59) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL24906442 0.80 PDE4D (0.53) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL10860621 0.80 KDM4E (0.51) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL31278376 0.79 KDM4E (0.48) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL7715367 0.79 HPGD (0.48) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL28802616 0.79 CYP1A2 (0.49) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL18209960 0.79 PDE4D (0.56) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL30964220 0.79 MAPT (0.49) ALDH1A1HPGDHTTKDM4ERECQL
SCHEMBL3263632 0.77 CYP1A2 (0.47) ALDH1A1HPGDHTTKDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10220030-B2 Amino-quinolines as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-03-05 US disclosed
US-10220030-B2 Amino-quinolines as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-03-05 US disclosed
US-20180085365-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-03-29 US disclosed
US-20180085365-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-03-29 US disclosed
US-20180085365-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-03-29 US disclosed
US-20170128437-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2017-05-11 US disclosed
US-20170128437-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2017-05-11 US disclosed
US-20170128437-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2017-05-11 US disclosed
US-9604963-B2 Amino-quinolines as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-03-28 US disclosed
US-9604963-B2 Amino-quinolines as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-03-28 US disclosed
EP-2603218-A1 QUINOLYL AMINES AS KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-06-19 EP disclosed
WO-2012122011-A2 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-09-13 WO disclosed
WO-2012122011-A2 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-09-13 WO disclosed
WO-2012021580-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-02-16 WO disclosed
WO-2012021580-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-02-16 WO disclosed
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2012-02-16 US disclosed
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2012-02-16 US disclosed
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2012-02-16 US disclosed
WO-1985001732-A1 8-SUBSTITUTED PYRAZOLOPENTATHIEPINS AND RELATED COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-25 WO disclosed
EP-0138622-A2 8-substituted pyrazolopentathiepins and related compounds E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS ABL1, MAP3K20, MAP3K19 ALDH1A1 3151/4885HPGD 3069/4885HTT 3253/4885
US-10220030-B2 Amino-quinolines as kinase inhibitors ABL1, MAP3K3, MAP3K7 ALDH1A1 3743/4885HPGD 4040/4885HTT 4508/4885
US-20180085365-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K3, MAP3K7 ALDH1A1 3743/4885HPGD 4040/4885HTT 4508/4885
US-20170128437-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K3, MAP3K7 ALDH1A1 3743/4885HPGD 4040/4885HTT 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.